We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 24.00 | 0.20% | 11,808.00 | 11,792.00 | 11,796.00 | 11,876.00 | 11,728.00 | 11,728.00 | 1,485,402 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5370 | 25.99 | 182.72B |
From Mar 2020 to Mar 2025
LONDON--AstraZeneca PLC (AZN.LN) shares rose 5.5% on Friday after the company said the U.S. food and drug administration has accepted the first license application for its antibody called durvalumab, meant for the treatment of patients with bladder cancer.
Shares at 1515 GMT up 225.50 pence, or 5.6%, at 4346 pence valuing the company at GBP54.9 billion.
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter @OlgaCotaga
(END) Dow Jones Newswires
December 09, 2016 10:31 ET (15:31 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
